Breast Cancer
News
Exercise linked to fewer cardiovascular events in nonmetastatic breast cancer patients
Key clinical point: Exercise was linked to significantly reduced risk of cardiovascular events in women with nonmetastatic breast cancer,...
Article
Mining for information, participation in clinical trials
News
‘Extreme’ monitoring fails to boost survival in breast cancer patients
Key clinical point: Extreme use of disease-monitoring tests significantly elevates health care costs and provides no survival benefit. Major...
News
Tamoxifen benefits premenopausal breast cancer patients
Key clinical point: Premenopausal women with ER-positive breast cancer had significantly longer survival with 2 years of adjuvant tamoxifen,...
Commentary
The Perfect Storm: Delivery system reform and precision medicine for all
ACOs potentially could assist in closing the racial mortality gap, because provider groups will take responsibility for improving the health of a...
News
Pembrolizumab shows activity against advanced TNBC
Key clinical point: The immune checkpoint inhibitor pembrolizumab may be effective against metastatic triple-negative breast cancer. Major finding...
Conference Coverage
ACOSOG Z0011: Good long-term results with SLND without ALND
CHICAGO – Sentinel lymph node dissection without axillary lymph node dissection offers excellent regional control in select patients with early...
Original Report
Reaching high-risk underserved individuals for cancer genetic counseling by video-teleconferencing
News
Adding tomosynthesis may benefit women with dense breasts
Women with dense breasts may benefit from additional screening at the time of digital mammography, but the messages notifying these women of...
Conference Coverage
MammaPrint bests clinical factors in sparing patients from chemotherapy
Key clinical point: MammaPrint bests Adjuvant!
News
Neratinib not superior to trastuzumab
Key clinical point: Neratinib plus paclitaxel was found not superior to trastuzumab plus paclitaxel for ERBB2-positive metastatic breast cancer....